More ADHD Drug Production; Psilocybin vs Lexapro; Addiction a Chronic Brain Disease?

Amid ongoing shortages, the U.S. Drug Enforcement Administration is allowing 24% more production of Takeda Pharmaceuticals’ attention deficit-hyperactivity disorder (ADHD) drug lisdexamfetamine (Vyvanse) and its generics. (Reuters)

Is a chain of psychiatric hospitals detaining its patients to maximize insurance payments? (New York Times)

High-dose psilocybin yielded better treatment responses than placebo and escitalopram (Lexapro) in a meta-analysis of antidepressant trials. (The BMJ)

More than one in five people who died of a drug overdose in 2022 had a non-substance-related mental health disorder, most commonly depression or anxiety. (Morbidity and Mortality Weekly Report)

Kids with neurodevelopmental disorders had higher increases in BMI than peers without from 2004 to 2020, a Swedish cross-sectional study found. (JAMA Network Open)

Researchers in Schizophrenia argued for a stepwise treatment rationale for patients with early-stage schizophrenia that slightly diverges from established algorithms.

Suicide deaths were higher for cancer patients who did not undergo surgery. (JAMA Network Open)

Risk for dementia was significantly lower for Korean adults taking an SGLT-2 inhibitor versus a DPP-4 inhibitor for type 2 diabetes, a population-based cohort study found. (The BMJ)

The New York Times examined efforts to rethink whether addiction should be considered a chronic brain disease.

While telemedicine was only used in 13.9% of all alcohol use disorder medication initiations, it still “may play an important role” in the process, said researchers in JAMA Network Open.

Baseline cognition didn’t moderate the treatment effect of vortioxetine (Trintellix) on depressive symptoms, a pooled analysis of four trials suggested. (Journal of Clinical Psychiatry)

After two fatal New Jersey police shootings of people in mental health crises, a state policy will change how officers respond to mental health calls. (CBS News)